nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—TACR1—nerve—skin cancer	0.0307	0.479	CbGeAlD
Fosaprepitant—TACR1—connective tissue—skin cancer	0.0124	0.193	CbGeAlD
Fosaprepitant—TACR1—female reproductive system—skin cancer	0.00872	0.136	CbGeAlD
Fosaprepitant—TACR1—head—skin cancer	0.00729	0.114	CbGeAlD
Fosaprepitant—TACR1—lymph node—skin cancer	0.0051	0.0795	CbGeAlD
Fosaprepitant—Weight decreased—Temozolomide—skin cancer	0.00208	0.00222	CcSEcCtD
Fosaprepitant—Infestation NOS—Temozolomide—skin cancer	0.00205	0.00219	CcSEcCtD
Fosaprepitant—Infestation—Temozolomide—skin cancer	0.00205	0.00219	CcSEcCtD
Fosaprepitant—Thrombophlebitis—Docetaxel—skin cancer	0.00204	0.00218	CcSEcCtD
Fosaprepitant—Blood alkaline phosphatase increased—Docetaxel—skin cancer	0.00203	0.00217	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.00203	0.00217	CcSEcCtD
Fosaprepitant—Flushing—Bleomycin—skin cancer	0.00202	0.00216	CcSEcCtD
Fosaprepitant—Body temperature increased—Vemurafenib—skin cancer	0.00202	0.00216	CcSEcCtD
Fosaprepitant—Stomatitis—Temozolomide—skin cancer	0.002	0.00213	CcSEcCtD
Fosaprepitant—Urinary tract infection—Temozolomide—skin cancer	0.00199	0.00213	CcSEcCtD
Fosaprepitant—Insomnia—Imiquimod—skin cancer	0.00197	0.00211	CcSEcCtD
Fosaprepitant—Dyspnoea—Imiquimod—skin cancer	0.00194	0.00208	CcSEcCtD
Fosaprepitant—Somnolence—Imiquimod—skin cancer	0.00194	0.00207	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Fluorouracil—skin cancer	0.00193	0.00207	CcSEcCtD
Fosaprepitant—Erythema multiforme—Dactinomycin—skin cancer	0.00192	0.00206	CcSEcCtD
Fosaprepitant—Dyspepsia—Imiquimod—skin cancer	0.00192	0.00205	CcSEcCtD
Fosaprepitant—Erythema—Bleomycin—skin cancer	0.0019	0.00203	CcSEcCtD
Fosaprepitant—Decreased appetite—Imiquimod—skin cancer	0.0019	0.00203	CcSEcCtD
Fosaprepitant—Hot flush—Docetaxel—skin cancer	0.00189	0.00202	CcSEcCtD
Fosaprepitant—Infestation NOS—Fluorouracil—skin cancer	0.00189	0.00202	CcSEcCtD
Fosaprepitant—Infestation—Fluorouracil—skin cancer	0.00189	0.00202	CcSEcCtD
Fosaprepitant—Flushing—Dactinomycin—skin cancer	0.00189	0.00202	CcSEcCtD
Fosaprepitant—Hypersensitivity—Vemurafenib—skin cancer	0.00188	0.00201	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Imiquimod—skin cancer	0.00188	0.00201	CcSEcCtD
Fosaprepitant—Fatigue—Imiquimod—skin cancer	0.00188	0.00201	CcSEcCtD
Fosaprepitant—Menopausal symptoms—Docetaxel—skin cancer	0.00187	0.002	CcSEcCtD
Fosaprepitant—Pain—Imiquimod—skin cancer	0.00187	0.00199	CcSEcCtD
Fosaprepitant—Stomatitis—Fluorouracil—skin cancer	0.00184	0.00197	CcSEcCtD
Fosaprepitant—Conjunctivitis—Fluorouracil—skin cancer	0.00184	0.00196	CcSEcCtD
Fosaprepitant—Urinary tract infection—Fluorouracil—skin cancer	0.00184	0.00196	CcSEcCtD
Fosaprepitant—Asthenia—Vemurafenib—skin cancer	0.00184	0.00196	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Temozolomide—skin cancer	0.00183	0.00196	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Temozolomide—skin cancer	0.00182	0.00194	CcSEcCtD
Fosaprepitant—Pruritus—Vemurafenib—skin cancer	0.00181	0.00193	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Temozolomide—skin cancer	0.00181	0.00193	CcSEcCtD
Fosaprepitant—Lethargy—Docetaxel—skin cancer	0.0018	0.00193	CcSEcCtD
Fosaprepitant—Urethral disorder—Temozolomide—skin cancer	0.0018	0.00193	CcSEcCtD
Fosaprepitant—Feeling abnormal—Imiquimod—skin cancer	0.0018	0.00192	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Imiquimod—skin cancer	0.00178	0.00191	CcSEcCtD
Fosaprepitant—Hyponatraemia—Docetaxel—skin cancer	0.00178	0.0019	CcSEcCtD
Fosaprepitant—Erythema—Dactinomycin—skin cancer	0.00177	0.00189	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Bleomycin—skin cancer	0.00176	0.00188	CcSEcCtD
Fosaprepitant—Anaemia—Bleomycin—skin cancer	0.00175	0.00188	CcSEcCtD
Fosaprepitant—Diarrhoea—Vemurafenib—skin cancer	0.00175	0.00187	CcSEcCtD
Fosaprepitant—Erythema multiforme—Temozolomide—skin cancer	0.00174	0.00186	CcSEcCtD
Fosaprepitant—Urticaria—Imiquimod—skin cancer	0.00173	0.00185	CcSEcCtD
Fosaprepitant—Abdominal pain—Imiquimod—skin cancer	0.00172	0.00184	CcSEcCtD
Fosaprepitant—Body temperature increased—Imiquimod—skin cancer	0.00172	0.00184	CcSEcCtD
Fosaprepitant—Eye disorder—Temozolomide—skin cancer	0.00172	0.00184	CcSEcCtD
Fosaprepitant—Tinnitus—Temozolomide—skin cancer	0.00172	0.00183	CcSEcCtD
Fosaprepitant—Malaise—Bleomycin—skin cancer	0.00171	0.00183	CcSEcCtD
Fosaprepitant—Flushing—Temozolomide—skin cancer	0.00171	0.00182	CcSEcCtD
Fosaprepitant—Cardiac disorder—Temozolomide—skin cancer	0.00171	0.00182	CcSEcCtD
Fosaprepitant—Dizziness—Vemurafenib—skin cancer	0.00169	0.00181	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Fluorouracil—skin cancer	0.00169	0.0018	CcSEcCtD
Fosaprepitant—Angiopathy—Temozolomide—skin cancer	0.00167	0.00178	CcSEcCtD
Fosaprepitant—Immune system disorder—Temozolomide—skin cancer	0.00166	0.00178	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Temozolomide—skin cancer	0.00166	0.00177	CcSEcCtD
Fosaprepitant—Cough—Bleomycin—skin cancer	0.00166	0.00177	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Dactinomycin—skin cancer	0.00164	0.00176	CcSEcCtD
Fosaprepitant—Anaemia—Dactinomycin—skin cancer	0.00164	0.00175	CcSEcCtD
Fosaprepitant—Vomiting—Vemurafenib—skin cancer	0.00163	0.00174	CcSEcCtD
Fosaprepitant—Chest pain—Bleomycin—skin cancer	0.00162	0.00173	CcSEcCtD
Fosaprepitant—Abdominal pain upper—Docetaxel—skin cancer	0.00162	0.00173	CcSEcCtD
Fosaprepitant—Rash—Vemurafenib—skin cancer	0.00161	0.00172	CcSEcCtD
Fosaprepitant—Mental disorder—Temozolomide—skin cancer	0.00161	0.00172	CcSEcCtD
Fosaprepitant—Dermatitis—Vemurafenib—skin cancer	0.00161	0.00172	CcSEcCtD
Fosaprepitant—Hypersensitivity—Imiquimod—skin cancer	0.00161	0.00172	CcSEcCtD
Fosaprepitant—Headache—Vemurafenib—skin cancer	0.0016	0.00171	CcSEcCtD
Fosaprepitant—Erythema—Temozolomide—skin cancer	0.0016	0.00171	CcSEcCtD
Fosaprepitant—Malnutrition—Temozolomide—skin cancer	0.0016	0.00171	CcSEcCtD
Fosaprepitant—Discomfort—Bleomycin—skin cancer	0.0016	0.00171	CcSEcCtD
Fosaprepitant—Malaise—Dactinomycin—skin cancer	0.0016	0.00171	CcSEcCtD
Fosaprepitant—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.00159	0.0017	CcSEcCtD
Fosaprepitant—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.00159	0.0017	CcSEcCtD
Fosaprepitant—Dysgeusia—Temozolomide—skin cancer	0.00157	0.00168	CcSEcCtD
Fosaprepitant—Asthenia—Imiquimod—skin cancer	0.00156	0.00167	CcSEcCtD
Fosaprepitant—Alanine aminotransferase increased—Docetaxel—skin cancer	0.00156	0.00167	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Bleomycin—skin cancer	0.00155	0.00166	CcSEcCtD
Fosaprepitant—Oedema—Bleomycin—skin cancer	0.00155	0.00166	CcSEcCtD
Fosaprepitant—Pruritus—Imiquimod—skin cancer	0.00154	0.00165	CcSEcCtD
Fosaprepitant—Infection—Bleomycin—skin cancer	0.00154	0.00165	CcSEcCtD
Fosaprepitant—Nausea—Vemurafenib—skin cancer	0.00152	0.00162	CcSEcCtD
Fosaprepitant—Diarrhoea—Imiquimod—skin cancer	0.00149	0.00159	CcSEcCtD
Fosaprepitant—Discomfort—Dactinomycin—skin cancer	0.00149	0.00159	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Temozolomide—skin cancer	0.00149	0.00159	CcSEcCtD
Fosaprepitant—Anaemia—Temozolomide—skin cancer	0.00148	0.00158	CcSEcCtD
Fosaprepitant—Erythema—Fluorouracil—skin cancer	0.00148	0.00158	CcSEcCtD
Fosaprepitant—Angioedema—Temozolomide—skin cancer	0.00146	0.00156	CcSEcCtD
Fosaprepitant—Hypotension—Bleomycin—skin cancer	0.00145	0.00155	CcSEcCtD
Fosaprepitant—Oedema—Dactinomycin—skin cancer	0.00145	0.00154	CcSEcCtD
Fosaprepitant—Malaise—Temozolomide—skin cancer	0.00144	0.00154	CcSEcCtD
Fosaprepitant—Dizziness—Imiquimod—skin cancer	0.00144	0.00154	CcSEcCtD
Fosaprepitant—Infection—Dactinomycin—skin cancer	0.00144	0.00153	CcSEcCtD
Fosaprepitant—Palpitations—Temozolomide—skin cancer	0.00142	0.00151	CcSEcCtD
Fosaprepitant—Cough—Temozolomide—skin cancer	0.0014	0.00149	CcSEcCtD
Fosaprepitant—Vomiting—Imiquimod—skin cancer	0.00139	0.00148	CcSEcCtD
Fosaprepitant—Weight decreased—Docetaxel—skin cancer	0.00138	0.00148	CcSEcCtD
Fosaprepitant—Hypertension—Temozolomide—skin cancer	0.00138	0.00148	CcSEcCtD
Fosaprepitant—Dyspnoea—Bleomycin—skin cancer	0.00138	0.00148	CcSEcCtD
Fosaprepitant—Rash—Imiquimod—skin cancer	0.00138	0.00147	CcSEcCtD
Fosaprepitant—Dermatitis—Imiquimod—skin cancer	0.00137	0.00147	CcSEcCtD
Fosaprepitant—Headache—Imiquimod—skin cancer	0.00137	0.00146	CcSEcCtD
Fosaprepitant—Anaemia—Fluorouracil—skin cancer	0.00136	0.00146	CcSEcCtD
Fosaprepitant—Infestation—Docetaxel—skin cancer	0.00136	0.00146	CcSEcCtD
Fosaprepitant—Infestation NOS—Docetaxel—skin cancer	0.00136	0.00146	CcSEcCtD
Fosaprepitant—Anxiety—Temozolomide—skin cancer	0.00136	0.00145	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00135	0.00145	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.00135	0.00144	CcSEcCtD
Fosaprepitant—Discomfort—Temozolomide—skin cancer	0.00135	0.00144	CcSEcCtD
Fosaprepitant—Decreased appetite—Bleomycin—skin cancer	0.00135	0.00144	CcSEcCtD
Fosaprepitant—Dry mouth—Temozolomide—skin cancer	0.00133	0.00142	CcSEcCtD
Fosaprepitant—Stomatitis—Docetaxel—skin cancer	0.00133	0.00142	CcSEcCtD
Fosaprepitant—Pain—Bleomycin—skin cancer	0.00133	0.00142	CcSEcCtD
Fosaprepitant—Conjunctivitis—Docetaxel—skin cancer	0.00132	0.00142	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Temozolomide—skin cancer	0.00131	0.0014	CcSEcCtD
Fosaprepitant—Oedema—Temozolomide—skin cancer	0.00131	0.0014	CcSEcCtD
Fosaprepitant—Infection—Temozolomide—skin cancer	0.0013	0.00139	CcSEcCtD
Fosaprepitant—Nausea—Imiquimod—skin cancer	0.0013	0.00138	CcSEcCtD
Fosaprepitant—Nervous system disorder—Temozolomide—skin cancer	0.00128	0.00137	CcSEcCtD
Fosaprepitant—Feeling abnormal—Bleomycin—skin cancer	0.00128	0.00136	CcSEcCtD
Fosaprepitant—Skin disorder—Temozolomide—skin cancer	0.00127	0.00136	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Temozolomide—skin cancer	0.00126	0.00135	CcSEcCtD
Fosaprepitant—Chest pain—Fluorouracil—skin cancer	0.00126	0.00134	CcSEcCtD
Fosaprepitant—Decreased appetite—Dactinomycin—skin cancer	0.00126	0.00134	CcSEcCtD
Fosaprepitant—Fatigue—Dactinomycin—skin cancer	0.00125	0.00133	CcSEcCtD
Fosaprepitant—Discomfort—Fluorouracil—skin cancer	0.00124	0.00133	CcSEcCtD
Fosaprepitant—Pain—Dactinomycin—skin cancer	0.00124	0.00132	CcSEcCtD
Fosaprepitant—Urticaria—Bleomycin—skin cancer	0.00123	0.00132	CcSEcCtD
Fosaprepitant—Body temperature increased—Bleomycin—skin cancer	0.00122	0.00131	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Docetaxel—skin cancer	0.00122	0.0013	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Docetaxel—skin cancer	0.00121	0.00129	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Fluorouracil—skin cancer	0.0012	0.00129	CcSEcCtD
Fosaprepitant—Oedema—Fluorouracil—skin cancer	0.0012	0.00129	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Docetaxel—skin cancer	0.0012	0.00128	CcSEcCtD
Fosaprepitant—Urethral disorder—Docetaxel—skin cancer	0.0012	0.00128	CcSEcCtD
Fosaprepitant—Infection—Fluorouracil—skin cancer	0.0012	0.00128	CcSEcCtD
Fosaprepitant—Feeling abnormal—Dactinomycin—skin cancer	0.00119	0.00127	CcSEcCtD
Fosaprepitant—Insomnia—Temozolomide—skin cancer	0.00118	0.00126	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Dactinomycin—skin cancer	0.00118	0.00126	CcSEcCtD
Fosaprepitant—Nervous system disorder—Fluorouracil—skin cancer	0.00118	0.00126	CcSEcCtD
Fosaprepitant—Dyspnoea—Temozolomide—skin cancer	0.00117	0.00125	CcSEcCtD
Fosaprepitant—Somnolence—Temozolomide—skin cancer	0.00116	0.00124	CcSEcCtD
Fosaprepitant—Erythema multiforme—Docetaxel—skin cancer	0.00116	0.00124	CcSEcCtD
Fosaprepitant—Dyspepsia—Temozolomide—skin cancer	0.00115	0.00123	CcSEcCtD
Fosaprepitant—Eye disorder—Docetaxel—skin cancer	0.00114	0.00122	CcSEcCtD
Fosaprepitant—Abdominal pain—Dactinomycin—skin cancer	0.00114	0.00122	CcSEcCtD
Fosaprepitant—Body temperature increased—Dactinomycin—skin cancer	0.00114	0.00122	CcSEcCtD
Fosaprepitant—Hypersensitivity—Bleomycin—skin cancer	0.00114	0.00122	CcSEcCtD
Fosaprepitant—Decreased appetite—Temozolomide—skin cancer	0.00114	0.00121	CcSEcCtD
Fosaprepitant—Cardiac disorder—Docetaxel—skin cancer	0.00114	0.00121	CcSEcCtD
Fosaprepitant—Flushing—Docetaxel—skin cancer	0.00114	0.00121	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Temozolomide—skin cancer	0.00113	0.00121	CcSEcCtD
Fosaprepitant—Fatigue—Temozolomide—skin cancer	0.00113	0.0012	CcSEcCtD
Fosaprepitant—Hypotension—Fluorouracil—skin cancer	0.00113	0.0012	CcSEcCtD
Fosaprepitant—Pain—Temozolomide—skin cancer	0.00112	0.00119	CcSEcCtD
Fosaprepitant—Constipation—Temozolomide—skin cancer	0.00112	0.00119	CcSEcCtD
Fosaprepitant—Asthenia—Bleomycin—skin cancer	0.00111	0.00119	CcSEcCtD
Fosaprepitant—Angiopathy—Docetaxel—skin cancer	0.00111	0.00119	CcSEcCtD
Fosaprepitant—Immune system disorder—Docetaxel—skin cancer	0.00111	0.00118	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Docetaxel—skin cancer	0.0011	0.00118	CcSEcCtD
Fosaprepitant—Pruritus—Bleomycin—skin cancer	0.0011	0.00117	CcSEcCtD
Fosaprepitant—Insomnia—Fluorouracil—skin cancer	0.00109	0.00116	CcSEcCtD
Fosaprepitant—Feeling abnormal—Temozolomide—skin cancer	0.00108	0.00115	CcSEcCtD
Fosaprepitant—Dyspnoea—Fluorouracil—skin cancer	0.00107	0.00115	CcSEcCtD
Fosaprepitant—Mental disorder—Docetaxel—skin cancer	0.00107	0.00115	CcSEcCtD
Fosaprepitant—Somnolence—Fluorouracil—skin cancer	0.00107	0.00114	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Temozolomide—skin cancer	0.00107	0.00114	CcSEcCtD
Fosaprepitant—Erythema—Docetaxel—skin cancer	0.00107	0.00114	CcSEcCtD
Fosaprepitant—Malnutrition—Docetaxel—skin cancer	0.00107	0.00114	CcSEcCtD
Fosaprepitant—Hypersensitivity—Dactinomycin—skin cancer	0.00106	0.00114	CcSEcCtD
Fosaprepitant—Dyspepsia—Fluorouracil—skin cancer	0.00106	0.00113	CcSEcCtD
Fosaprepitant—Decreased appetite—Fluorouracil—skin cancer	0.00105	0.00112	CcSEcCtD
Fosaprepitant—Dysgeusia—Docetaxel—skin cancer	0.00104	0.00111	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00104	0.00111	CcSEcCtD
Fosaprepitant—Urticaria—Temozolomide—skin cancer	0.00104	0.00111	CcSEcCtD
Fosaprepitant—Asthenia—Dactinomycin—skin cancer	0.00104	0.00111	CcSEcCtD
Fosaprepitant—Abdominal pain—Temozolomide—skin cancer	0.00103	0.0011	CcSEcCtD
Fosaprepitant—Body temperature increased—Temozolomide—skin cancer	0.00103	0.0011	CcSEcCtD
Fosaprepitant—Pain—Fluorouracil—skin cancer	0.00103	0.0011	CcSEcCtD
Fosaprepitant—Muscle spasms—Docetaxel—skin cancer	0.00102	0.00109	CcSEcCtD
Fosaprepitant—Feeling abnormal—Fluorouracil—skin cancer	0.000992	0.00106	CcSEcCtD
Fosaprepitant—Diarrhoea—Dactinomycin—skin cancer	0.000989	0.00106	CcSEcCtD
Fosaprepitant—Vomiting—Bleomycin—skin cancer	0.000985	0.00105	CcSEcCtD
Fosaprepitant—Anaemia—Docetaxel—skin cancer	0.000984	0.00105	CcSEcCtD
Fosaprepitant—Rash—Bleomycin—skin cancer	0.000977	0.00104	CcSEcCtD
Fosaprepitant—Dermatitis—Bleomycin—skin cancer	0.000976	0.00104	CcSEcCtD
Fosaprepitant—Hypersensitivity—Temozolomide—skin cancer	0.000963	0.00103	CcSEcCtD
Fosaprepitant—Urticaria—Fluorouracil—skin cancer	0.000957	0.00102	CcSEcCtD
Fosaprepitant—Syncope—Docetaxel—skin cancer	0.000955	0.00102	CcSEcCtD
Fosaprepitant—Body temperature increased—Fluorouracil—skin cancer	0.000952	0.00102	CcSEcCtD
Fosaprepitant—Palpitations—Docetaxel—skin cancer	0.000941	0.00101	CcSEcCtD
Fosaprepitant—Asthenia—Temozolomide—skin cancer	0.000938	0.001	CcSEcCtD
Fosaprepitant—Loss of consciousness—Docetaxel—skin cancer	0.000936	0.001	CcSEcCtD
Fosaprepitant—Cough—Docetaxel—skin cancer	0.000929	0.000993	CcSEcCtD
Fosaprepitant—Pruritus—Temozolomide—skin cancer	0.000925	0.000988	CcSEcCtD
Fosaprepitant—Nausea—Bleomycin—skin cancer	0.00092	0.000984	CcSEcCtD
Fosaprepitant—Hypertension—Docetaxel—skin cancer	0.00092	0.000983	CcSEcCtD
Fosaprepitant—Vomiting—Dactinomycin—skin cancer	0.000919	0.000982	CcSEcCtD
Fosaprepitant—Rash—Dactinomycin—skin cancer	0.000911	0.000974	CcSEcCtD
Fosaprepitant—Chest pain—Docetaxel—skin cancer	0.000907	0.000969	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000901	0.000962	CcSEcCtD
Fosaprepitant—Diarrhoea—Temozolomide—skin cancer	0.000894	0.000956	CcSEcCtD
Fosaprepitant—Hypersensitivity—Fluorouracil—skin cancer	0.000887	0.000948	CcSEcCtD
Fosaprepitant—Dry mouth—Docetaxel—skin cancer	0.000887	0.000948	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Docetaxel—skin cancer	0.000869	0.000929	CcSEcCtD
Fosaprepitant—Oedema—Docetaxel—skin cancer	0.000869	0.000929	CcSEcCtD
Fosaprepitant—Dizziness—Temozolomide—skin cancer	0.000864	0.000924	CcSEcCtD
Fosaprepitant—Infection—Docetaxel—skin cancer	0.000864	0.000923	CcSEcCtD
Fosaprepitant—Nausea—Dactinomycin—skin cancer	0.000858	0.000917	CcSEcCtD
Fosaprepitant—Shock—Docetaxel—skin cancer	0.000855	0.000914	CcSEcCtD
Fosaprepitant—Nervous system disorder—Docetaxel—skin cancer	0.000852	0.000911	CcSEcCtD
Fosaprepitant—Pruritus—Fluorouracil—skin cancer	0.000852	0.000911	CcSEcCtD
Fosaprepitant—Skin disorder—Docetaxel—skin cancer	0.000844	0.000902	CcSEcCtD
Fosaprepitant—Vomiting—Temozolomide—skin cancer	0.000831	0.000888	CcSEcCtD
Fosaprepitant—Rash—Temozolomide—skin cancer	0.000824	0.000881	CcSEcCtD
Fosaprepitant—Diarrhoea—Fluorouracil—skin cancer	0.000824	0.000881	CcSEcCtD
Fosaprepitant—Dermatitis—Temozolomide—skin cancer	0.000823	0.00088	CcSEcCtD
Fosaprepitant—Headache—Temozolomide—skin cancer	0.000819	0.000875	CcSEcCtD
Fosaprepitant—Hypotension—Docetaxel—skin cancer	0.000812	0.000868	CcSEcCtD
Fosaprepitant—Dizziness—Fluorouracil—skin cancer	0.000796	0.000851	CcSEcCtD
Fosaprepitant—Insomnia—Docetaxel—skin cancer	0.000786	0.00084	CcSEcCtD
Fosaprepitant—Nausea—Temozolomide—skin cancer	0.000776	0.00083	CcSEcCtD
Fosaprepitant—Dyspnoea—Docetaxel—skin cancer	0.000775	0.000828	CcSEcCtD
Fosaprepitant—Somnolence—Docetaxel—skin cancer	0.000773	0.000826	CcSEcCtD
Fosaprepitant—Vomiting—Fluorouracil—skin cancer	0.000766	0.000818	CcSEcCtD
Fosaprepitant—Dyspepsia—Docetaxel—skin cancer	0.000765	0.000818	CcSEcCtD
Fosaprepitant—Rash—Fluorouracil—skin cancer	0.000759	0.000811	CcSEcCtD
Fosaprepitant—Dermatitis—Fluorouracil—skin cancer	0.000759	0.000811	CcSEcCtD
Fosaprepitant—Decreased appetite—Docetaxel—skin cancer	0.000756	0.000807	CcSEcCtD
Fosaprepitant—Headache—Fluorouracil—skin cancer	0.000754	0.000806	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Docetaxel—skin cancer	0.00075	0.000802	CcSEcCtD
Fosaprepitant—Fatigue—Docetaxel—skin cancer	0.000749	0.000801	CcSEcCtD
Fosaprepitant—Pain—Docetaxel—skin cancer	0.000743	0.000794	CcSEcCtD
Fosaprepitant—Constipation—Docetaxel—skin cancer	0.000743	0.000794	CcSEcCtD
Fosaprepitant—Feeling abnormal—Docetaxel—skin cancer	0.000716	0.000765	CcSEcCtD
Fosaprepitant—Nausea—Fluorouracil—skin cancer	0.000715	0.000764	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Docetaxel—skin cancer	0.000711	0.00076	CcSEcCtD
Fosaprepitant—Body temperature increased—Docetaxel—skin cancer	0.000687	0.000734	CcSEcCtD
Fosaprepitant—Abdominal pain—Docetaxel—skin cancer	0.000687	0.000734	CcSEcCtD
Fosaprepitant—Hypersensitivity—Docetaxel—skin cancer	0.00064	0.000684	CcSEcCtD
Fosaprepitant—Asthenia—Docetaxel—skin cancer	0.000624	0.000666	CcSEcCtD
Fosaprepitant—Pruritus—Docetaxel—skin cancer	0.000615	0.000657	CcSEcCtD
Fosaprepitant—Diarrhoea—Docetaxel—skin cancer	0.000595	0.000636	CcSEcCtD
Fosaprepitant—Dizziness—Docetaxel—skin cancer	0.000575	0.000614	CcSEcCtD
Fosaprepitant—Vomiting—Docetaxel—skin cancer	0.000553	0.000591	CcSEcCtD
Fosaprepitant—Rash—Docetaxel—skin cancer	0.000548	0.000586	CcSEcCtD
Fosaprepitant—Dermatitis—Docetaxel—skin cancer	0.000548	0.000585	CcSEcCtD
Fosaprepitant—Headache—Docetaxel—skin cancer	0.000545	0.000582	CcSEcCtD
Fosaprepitant—Nausea—Docetaxel—skin cancer	0.000516	0.000552	CcSEcCtD
